We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 1,014

Federal Court criticizes examination guidelines on medical uses in Canada

  • Marks & Clerk
  • -
  • Canada
  • -
  • January 16 2015

The Canadian Intellectual Property Office (CIPO) released in 2013 examination guidelines titled "Examination Practice Respecting Medical Uses"

Federal court overturns Commissioner of Patents: claims with fixed dosages and dosing schedules held not to be methods of medical treatment

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • January 16 2015

In AbbVie Biotechnology Ltd v Canada (Attorney General) "AbbVie" the Federal Court allowed AbbVie's appeal of a decision by the Commissioner of

Court finds claims do not cover method of medical treatment, orders that they issue

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 19 2015

In this decision, AbbVie brought a judicial review of a decision of the Commissioner of Patents refusing to issue its patent. The issue was whether

Federal court sets aside Minister of Health’s decision to issue NOCs based on cross-referenced administrative drug submissions

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • January 22 2015

The Federal Court released two decisions on December 19, 2014 granting the innovators’ applications to set aside the Minister’s decision to issue

Minister’s decision to grant NOA to generic company set aside, as the generic did not comply with the NOC regulations

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 19 2015

In this proceeding, Pfizer sought to judicially review the Minister of Health’s decision to grant Teva a NOC for exemestane. A company called GMP

Court refused to grant protective order covering NOA

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 19 2015

In the context of a proceeding brought pursuant to the NOC Regulations, Mylan sought a confidentiality that would allow it to designate portions of

Federal Court revisits the issue of medical uses

  • Smart & Biggar/Fetherstonhaugh
  • -
  • Canada
  • -
  • January 22 2015

In AbbVie Biotechnology Ltd v Canada (Attorney General), 2014 FC 1251, rendered December 22, 2014, the Federal Court allowed AbbVie's appeal from a

Canadian online pharmacy enjoined from selling Indian generics to US customers

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • October 2 2014

Global Pharmacy Canada (“GPC”) is an online prescription drug retailer that sells drugs sourced in India to customers in the United States. GPC is

Teva v Pfizer, or the “Viagra saga”: if there is no quid proper disclosure there can be no quo exclusive monopoly rights

  • Fasken Martineau DuMoulin LLP
  • -
  • Canada
  • -
  • November 19 2012

Sildenafil is the active ingredient in Viagra, the blockbuster potency-enhancing drug marketed by Pfizer

Generic companies seek leave to appeal to the Supreme Court of Canada on the “promise of the patent”

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • January 9 2015

On December 23, 2014, Apotex Inc. and Mylan Pharmaceuticals ULC each filed Supreme Court of Canada (SCC) applications for leave to appeal the Federal